MTLS  Group Excellence

Backing the earliest steps
in medicine's next generation.

A decade inside the regulatory and clinical work behind CE and FDA — written into the earliest checks.

Enter the firm ↓
Copenhagen  ·  Health-tech investment
Vol. i  ·  mmxxvi
i. Thesis

What we back.

i.

MedTech devices.

Class II and above hardware where the regulatory pathway and clinical evidence are the moat.

ii.

Software as a Medical Device.

SaMD and AI/ML in medicine. Where risk classification is real and QMS discipline is real.

iii.

Diagnostics & life-sciences tools.

IVDR-adjacent diagnostics and instruments used in the lab and the clinic. Not therapeutics.

ii. Invest

How we invest.

Personal capital. Angel checks. One-page decisions. No fund, no committee, no term-sheet theatre.

First check
€25–75k
Occasionally up to €150k when leading a small angel round.
To decision
14days
From first meeting, or a clear no with the reason.
Cadence
6–10/ yr
Small book by design; every position gets attention.
Or

In place of cash — sweat equity.

When time and hands-on expertise are the more useful contribution than capital, we may propose sweat equity in place of — or alongside — a cheque. Allocated hours in regulatory pathway, clinical evidence, notified-body prep, and RA/QA hiring, exchanged for a small equity position on standard terms.

Most suited for very early stage

Stage

Pre-seed and seed.

We come in at the point where the regulatory pathway and clinical evidence plan are being drafted. An operator with reps compresses six months of learning into a two-hour whiteboard.

Geography

EU-first, opportunistically global.

Nordic and European founders sit inside our network and timezone. The current book spans Denmark, New Zealand, and the United States.

Terms

SAFE or priced. No games.

We follow standard terms of the round. We don't lead process on terms unless we're leading the round. No board seats at first check.

Beyond the check

Time on the tools.

Regulatory pathway review · clinical evidence plan · CE/FDA narrative · first RA/QA hire calls · introductions to notified bodies and follow-on capital. Priced into the check.

We back
  • Founders who name their MDR class on the first slide.
  • Devices, SaMD, diagnostics with a clinical evidence path.
  • Teams that treat the QMS as strategy, not overhead.
  • Founders where our operating time is worth more than our cheque.
We don't back
  • Therapeutics and drug discovery.
  • Consumer wellness with an undefensible medical claim.
  • Services-first businesses without a product wedge.
  • Anything that pretends the regulator won't matter for three years.
Send us a deck →
iii. Portfolio

Companies we hold.

Image slot · flagship

Medflow

Denmark
MedTech infrastructure · Flagship

A family of tools that help MedTech and BioTech companies build and certify their medical devices — regulatory and clinical documentation, CERs, PMS/PSUR, MDR workflows.

→
Image slot

Nervapax

Denmark
Neurology

Building for one of neurology's most under-served indications — cluster headache — from Copenhagen.

→
Image slot

DreamFlo

New Zealand
Respiratory · CPAP

Sleep-medicine hardware — a CPAP company out of New Zealand, in a category the incumbents haven't rethought in a decade.

website in progress
Image slot

Cortex

Neuro-diagnostic · Chiropractic

The first robotic brain scanner built for chiropractic — real-time EEG and HRV visualised during patient adjustments. Brain health, made visible.

→
iv. About

Behind the checks.

Medicine's hardest work happens at the start. Regulatory pathway, clinical evidence, the first RA/QA hire — decisions in the earliest stretch that determine whether a device ever reaches a patient.

MTLS Group exists for that stretch. Personal capital, or operating time on the tools, for MedTech, SaMD, and diagnostics founders who take the standards — and the timelines — seriously.

Small book by design. Behind the vehicle: Morten Togo Sørensen, MD — a decade of regulatory and clinical work sits behind every check.

v. Questions

Honest questions.

How do you decide, and how fast?

First meeting to yes-or-no in fourteen days. If we can't get there, we say so on day one. Most nos come with a reason and, where possible, a next introduction.

Do you lead rounds?

Rarely. We're built to be the second or third call, not the first. When we lead, it's a small angel round with founders we already know.

Do you take board seats?

Not at first check. If the position grows and the founder wants one, we consider it — with a clear scope and a clear end.

How does MTLS Group relate to Medflow?

MTLS Group is the investment vehicle. Medflow is a separate operating company held as a portfolio position. The two brands are legally and visually distinct — MTLS Group does not build product, and Medflow is not spoken for on this site.

What if my company doesn't fit the thesis?

We say so quickly, and — where we can — we point you at investors who are the right fit. That's the more useful thing we can do.

vi. Contact

Send us a deck.

Founders

Fifteen minutes to a real answer.

A short deck (10–12 slides) is enough. If we have questions, we write back within a week. If it's a fit, we book time.

Co-investors & diligence

Second opinions, welcomed.

A small number of diligence engagements per quarter for boards and co-investors looking at MedTech, SaMD, or diagnostics deals.